Whole-genome sequencing analysis of clozapine-induced myocarditis

Journal: Pharmacogenomics J

Publication date: 2022

Journal: Pharmacogenomics J

Publication Year: 2022

Authors & Co-authors: 

Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity

Journal: Pharmacogenomics J

Publication date: 2020

Journal: Pharmacogenomics J

Publication Year: 2020

Authors & Co-authors: 

Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada.

Journal: Pharmacogenomics

Publication date: 2024

Journal: Pharmacogenomics

Publication Year: 2024

Authors & Co-authors:  Maruf Shields Fryza Wondrasek Leong Kowalec Bousman

Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.

Journal: The pharmacogenomics journal

Publication date: 2021

Journal: The pharmacogenomics journal

Publication Year: 2021

Authors & Co-authors:  Lesche Dorothea D Mostafa Sam S Everall Ian I Pantelis Christos C Bousman Chad A CA

Whole-genome sequencing analysis of clozapine-induced myocarditis.

Journal: The pharmacogenomics journal

Publication date: 2022

Journal: The pharmacogenomics journal

Publication Year: 2022

Authors & Co-authors:  Narang Ankita A Lacaze Paul P Ronaldson Kathlyn J KJ McNeil John J JJ Jayaram Mahesh M Thomas Naveen N Sellmer Rory R Crockford David N DN Stowe Robert R Greenway Steven C SC

H3Africa: current perspectives.

Journal: Pharmacogenomics and personalized medicine

Publication date: 

Journal: Pharmacogenomics and personalized medicine

Publication Year: 

Authors & Co-authors:  Mulder Nicola N Abimiku Alash'le A Adebamowo Sally N SN de Vries Jantina J Matimba Alice A Olowoyo Paul P Ramsay Michele M Skelton Michelle M Stein Dan J DJ